Vice President, Clinical Development Program Leader
Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
Posted Oct 19, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Offered From the posting source checked Nov 18, 2026
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Nov 20, 2026
- Salary
- Not verified
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $81,444 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +6.9% - Faster than average
Matched to SOC 29-1141 - Healthcare aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 18, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Vice President, Clinical Development Program Leader PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Vice President, Clinical Development Program Leader Company Background Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. The company's medication, Rezdiffra (resmetirom), is the first and only FDA and European Commission-approved treatment for MASH with moderate to advanced fibrosis. Madrigal's pipeline includes ongoing Phase 3 trials and new assets in early development. Role Overview The Vice President, Clinical Development
Read the full description at madrigalpharma.wd501.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Vice President, Global Medical Lead - MASH
Madrigal Pharmaceuticals Inc - 2 Locations
Vice President, Clinical Development
Beam Therapeutics Inc - Cambridge, MA
Vice President / Senior Vice President, Clinical Development (AID)
Janux Therapeutics Inc - San Diego, CA
Senior Vice President, Late-Stage Clinical Development
Revolution Medicines - Redwood City, California, United States